Get started
Author

Elie G. Dib

Polypharmacy, Potentially Inappropriate Medications, and Drug-Drug Interactions in Vulnerable Older Adults With Advanced Cancer Initiating Cancer Treatment
2022 · Erika Ramsdale, Mostafa Mohamed, et al. · The Oncologist · 93
PDF
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ
2024 · E. Shelley Hwang, Terry Hyslop, et al. · JAMA · 87
PDF
Palbociclib in Patients With Non–Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
2020 · Eugene R. Ahn, Pam K. Mangat, et al. · JCO Precision Oncology · 69
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma
2022 · Steven F. Powell, Miroslaw Mazurczak, et al. · Investigational New Drugs · 62
Concurrent Chemoradiation ± Atezolizumab (atezo) in Limited-Stage Small Cell Lung Cancer (LS-SCLC): Results of NRG Oncology/Alliance LU005
2024 · K. Higgins, C. Hu, et al. · International Journal of Radiation Oncology*Biology*Physics · 56
PDF
The Relationship Between Frailty and Emotional Health in Older Patients with Advanced Cancer
2021 · Nikesha Gilmore, Lee Kehoe, et al. · The Oncologist · 38
PDF
Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy
2004 · Elie G. Dib, Jainulabdeen J. Ifthikharuddin, et al. · Leukemia Research · 31
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005
2026 · Kristin A. Higgins, Chen Hu, et al. · Journal of Clinical Oncology · 25
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
2024 · Timothy L. Cannon, Michael Rothe, et al. · Journal of Clinical Oncology · 24
Multifocal Myoclonus Induced by Trimethoprim–Sulfamethoxazole Therapy in a Patient with Nocardia Infection
2003 · Elie G. Dib, Steven Bernstein, et al. · New England Journal of Medicine · 19
PDF
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ
2024 · Ann H. Partridge, Terry Hyslop, et al. · JAMA Oncology · 17
PDF
Nonhemolytic, Nonmotile Gram-Positive Rods Indicative of Bacillus anthracis
2003 · Elie G. Dib, Samar A. Dib, et al. · Emerging infectious diseases · 17
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).
2023 · Jennifer Ann Woyach, Jun Yin, et al. · Journal of Clinical Oncology · 15
Case reports and the fight against cancer
2008 · Elie G Dib, Michael R Kidd, et al. · Journal of Medical Case Reports · 15
PDF
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study
2023 · Apar K. Ganti, Michael Rothe, et al. · JCO Precision Oncology · 13
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study
2023 · Eddy S. Yang, Susan Halabi, et al. · JCO Precision Oncology · 12
Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study
2018 · Steven F. Powell, Elie G. Dib, et al. · JCO Precision Oncology · 11
Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management
2004 · Elie G Dib · Leukemia Research · 11
Palbociclib (P) in patients (pts) with non-small cell lung cancer (NSCLC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
2019 · Eugene R Ahn, Pam K. Mangat, et al. · Journal of Clinical Oncology · 10
Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
2023 · Timothy Lewis Cannon, Michael Rothe, et al. · Journal of Clinical Oncology · 8
PDF
Exploring geriatric assessment‐driven rehabilitation referral patterns and its influence on functional outcomes and survival in older adults with advanced cancer
2024 · Rachelle Brick, Marielle Jensen‐Battaglia, et al. · Journal of the American Geriatrics Society · 6
PDF
A randomized trial of consolidation-targeted adjuvant therapy with encorafenib and cetuximab versus usual care for patients with stage II/III BRAF V600E colon cancer: Alliance for Clinical Trials in Oncology A022004.
2023 · Rona Yaeger, Qian Shi, et al. · Journal of Clinical Oncology · 6
Olaparib (O) in patients (pts) with colorectal cancer (CRC) with ATM mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
2023 · Deepti Behl, Michael Rothe, et al. · Journal of Clinical Oncology · 6
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
2019 · Jennifer Woyach, Amy S. Ruppert, et al. · Blood · 6
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma
2026 · Shaji Kumar, Susanna Jacobus, et al. · New England Journal of Medicine · 5
PDF
Works count: 53
Citation count: 695
H-index: 14
I10-index: 19
Year
Topic
Type